scholarly journals Expression and Diagnostic Efficacy of miR-126-5p and miR-34c-3p in Serum Extracellular Vesicles of Non-Small Cell Lung Cancer Patients

2021 ◽  
Author(s):  
Jie Zhao ◽  
Wenlu Hang ◽  
Qian Wang ◽  
Yonghong Xu
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Small Cell Lung Cancer ◽  
Poor Prognosis ◽  
Clinical Stage ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Metastasis ◽  
Nsclc Patients

Abstract Background: Non-small cell lung cancer (NSCLC) is a disease with quite grave prognosis. This study explored the diagnostic efficiency of miR-126-5p and miR-34c-3p in serum extracellular vesicles (EVs) in NSCLC patients.Methods: Serum EVs were extracted from NSCLC patients and healthy people and verified. The expression of miR-126-5p and miR-34c-3p in serum EVs were tested. Correlation of miR-126-5p and miR-34c-3p expression and diagnosis, prognosis and pathological characteristics (age, gender, tumor size, clinical stage, and lymph node metastasis) of NSCLC patients was analyzed. The downstream targets of miR-126-5p and miR-34c-3p were predicted and their roles in diagnosis and prognosis of NSCLC patients were evaluated.Results: miR-126-5p and miR-34c-3p were poorly expressed in serum EVs of NSCLC patients and their low expressions were associated with clinical stage, lymph node metastasis and prognosis of NSCLC patients and could be used as biomarkers for diagnosis. As the common target genes of miR-126-5p and miR-34c-3p, LYPLA1 and CDK6 were highly expressed in serum EVs and were associated with poor prognosis in NSCLC patients.Conclusion: Lowly expressed miR-126-5p and miR-34c-3p in serum EVs of NSCLC patients can serve as biomarkers for diagnosis and are linked with prognosis. As common targets of miR-126-5p and miR-34c-3p, LYPLA1 and CDK6 are also associated with poor prognosis in NSCLC patients.

scholarly journals Assessment of non‐lobe‐specific lymph node metastasis in clinical stage IA non‐small cell lung cancer

2019 ◽  
Vol 10 (7) ◽  
pp. 1597-1604 ◽  
Author(s):  
Zhirong Zhang ◽  
Jinbai Miao ◽  
Qirui Chen ◽  
Yili Fu ◽  
Hui Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Small Cell Lung Cancer ◽  
Clinical Stage ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Metastasis ◽  
Clinical Stage Ia ◽  
Stage Ia

Genetic variants in NPAS2 gene and clinical outcomes of resectable non-small-cell lung cancer

2021 ◽  
Vol 17 (7) ◽  
pp. 795-805
Author(s):  
Yiwei He ◽  
Gang Wang ◽  
Qian Wang ◽  
Zheng Zhao ◽  
Lu Gan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Genetic Variants ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Metastasis ◽  
Nsclc Patients

Background: A series of studies have demonstrated that NPAS2 plays a critical role in the development and progression of several cancers. However, the association between genetic variants in the  NPAS2 gene and the clinical outcome of patients with non-small-cell lung cancer (NSCLC) has not been investigated. Methods: Six functional SNPs in NPAS2 were selected and genotyped using the Sequenom iPLEX genotyping system in a cohort of 484 Chinese NSCLC patients undergoing surgery. Multivariate Cox proportional hazards model were used for the prognosis analysis. Results: We found that SNP rs2305158 exhibited a significant association with overall survival of NSCLC patients in the dominant model (hazard ratio [HR]: 0.68; 95% CI: 0.49–0.95; p = 0.02). Lymph node metastasis was significantly associated with increased death risk (HR: 1.73; 95% CI: 1.24–2.40; p = 0.001) in patients with the homozygous wildtype (WW) genotype of rs2305158. However, no significant association was observed between them in patients carrying a heterozygous variant (WV) or homozygous variant (VV) genotype of rs2305158. Finally, in the joint and interaction analysis, the patients carrying homozygous wildtype (WW) genotype and lymph node metastasis from N1 to N3 conferred a significant increased effect on death (HR: 2.29; 95% CI: 1.40–3.76; p = 0.001). Conclusions: Our results suggest that NPAS2 polymorphisms may serve as an independent prognostic marker for NSCLC patients.

scholarly journals Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Yi Wang ◽  
Yan Wang ◽  
Jialong Li ◽  
Jue Li ◽  
Guowei Che
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Small Cell Lung Cancer ◽  
Pik3ca Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pik3ca Gene ◽  
Node Metastasis ◽  
Nsclc Patients

Aim. To explore the clinicopathological and prognostic role of PIK3CA gene mutation and expression in non-small-cell lung cancer (NSCLC) patients. Methods. A systematic and comprehensive literature search was conducted through EMBASE (via OVID), Web of Science, and PubMed. Relative risks (RRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were combined to evaluate the relationship of the PIK3CA gene with clinicopathological parameters and the survival of NSCLC patients, respectively. Results. A total of 13 studies involving 3908 patients were analyzed in our study. Only lymph node metastasis status had an association with PIK3CA mutation (RR=2.823; 95% CI: 1.128-7.065; P=0.029). The results indicated that PICK3CA mutation was related with overall survival (OS) (HR=1.55; 95% CI: 1.13-2.13; P=0.007), progression-free survival (PFS) (HR=1.48; 95% CI: 1.06-2.08; P=0.023), and cancer-specific survival (CSS) (HR=2.63; 95% CI: 1.00-6.92; P=0.005). Furthermore, PIK3CA high expression was more prevalent in NSCLC patients with smoking history (RR=2.42; 95% CI: 1.04-5.61; P=0.040). However, no significant relation between PIK3CA expression and OS was found (HR=0.80; 95% CI: 0.58-1.12; P=0.193). Conclusion. PIK3CA mutation may affect lymph node metastasis and serve as a promising prognostic factor, and smoking may be related with PIK3CA high expression in NSCLC patients. However, more well-designed prospective researches are needed to verify the abovementioned findings.

scholarly journals Correlation between loss of Smad4 and clinical parameters of non-small cell lung cancer: an observational cohort study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xiangjun Guo ◽  
Mengmeng Li ◽  
Xin Wang ◽  
Yun Pan ◽  
Jiashu Li
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Serum Concentration ◽  
Small Cell Lung Cancer ◽  
Clinical Stage ◽  
Small Cell ◽  
Healthy Individuals ◽  
Small Cell Lung ◽  
Node Metastasis

Abstract Background SMAD4 has been found to be inactivated to varying degrees in many types of cancer; the purpose of this study was to investigate the correlation between SMAD4 expression in non-small cell lung cancer (NSCLC) and clinical pathological parameters. Methods The serum concentration of SMAD4 was measured by enzyme-linked immunosorbent assay and its histological expression was quantified by immunohistochemistry. Results The serum concentration of Smad4 in patients with NSCLC was lower than that in benign lung disease patients and healthy individuals (P < 0.001) and its concentration was related to the histological classification, pathological differentiation, lymphatic metastasis and clinical stage of NSCLC. The sensitivity and specificity of serum Smad4 were 91.56% and 61.56% for screening NSCLC from healthy individuals and 84.55% and 60.36% for screening NSCLC from patients with benign lung disease. Logistic regression analysis showed that the degree of cell differentiation (P < 0.001), lymph node metastasis (P < 0.001) and clinical stage of NSCLC (P = 0.007) affected the expression of Smad4, and had a strong correlation with the expression of Smad4. The expression of Smad4 in NSCLC tissues was lower than that in normal lung tissues (P = 0.009) and its expression was related to the degree of tissue differentiation, lymph node metastasis and clinical stage (P < 0.05). Conclusions The downregulation or deletion of Smad4 is related to the malignant biological behavior of NSCLC and serum Smad4 could be considered as a potential molecular indicator for diagnosis and evaluation of NSCLC.

Factors involved in lymph node metastasis in clinical stage I non-small cell lung cancer—From studies of 604 surgical cases

Lung Cancer ◽  
2007 ◽  
Vol 57 (3) ◽  
pp. 311-316 ◽  
Author(s):  
Nobukazu Fuwa ◽  
Tetsuya Mitsudomi ◽  
Takashi Daimon ◽  
Yasushi Yatabe ◽  
Masahiro Shinoda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Stage ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
Node Metastasis
Sign in / Sign up

Export Citation Format

Share Document